Immune effector cell pathways (IECP)

Immune effector cell pathways refer to the complex network of signaling cascades and cellular processes that govern the activation and function of immune cells responsible for eliminating pathogens or malignant cells. These pathways involve various cell types, including T cells, Natural Killer (NK) cells, and macrophages, which utilize mechanisms such as direct cytotoxicity and the secretion of pro-inflammatory cytokines. In the context of oncology, these pathways are frequently modulated by immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, to enhance the anti-tumor response. However, because 'Immune effector cell pathways' represents a broad biological category rather than a specific protein or receptor, it is not considered a single therapeutic target in the traditional pharmacological sense. Instead, drug discovery efforts focus on specific molecular components within these pathways, such as PD-1, CTLA-4, or various interleukins, to achieve therapeutic effects.

Other names

Immune effector pathwaysEffector cell signalingImmune activation pathways

Not applicable as this is a broad biological pathway category rather than a single molecular target.